Observational analysis reveals comparable outcomes with HIFU for prostate and pancreatic cancers, suggesting a new therapeutic approach.
High-Intensity Focused Ultrasound (HIFU) represents a groundbreaking advancement in non-invasive therapeutic intervention, offering precise tissue ablation with minimal damage to surrounding structures. This paper explores its validated clinical applications across prostate cancer, pancreatic cancer, and refractory hypertension. Recent trials demonstrate that HIFU achieves comparable oncologic outcomes to standard therapies while preserving organ function, improving quality of life, and reducing treatment-related complications. Its expanding utility in neuromodulation further highlights its interdisciplinary impact. With ongoing technological refinement and clinical integration, HIFU is poised to become a transformative modality in the future of precision medicine.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: